FUNCTIONAL MEDICINE BLOG
Includes over 800 monographs reporting on emerging studies in the medical and scientific literature of practical clinical importance, easily searched for content.
Bisphosphonates increase risk of atypical fracture
More evidence that bisphosphonates (Fosamax® (alendronate), Boniva® (ibandronate), Actonel® (risedronate), Reclast® (zoledronic acid), etc.) by increasing bone density while sacrificing bone health increase the risk of atypical fractures is presented in a study just published in the journal Family Practice.
Zoledronic acid ups bone density but doesn't reduce fractures
Zoledronic acid (Zometa®, Zomera®, Reclast®, Aclasta®), like other bisphosphonate drugs, slows bone resorption by binding to bone and inducing apoptosis (killing) osteoclasts, the bone cells that clear old bone to make room for new. A study just published in JAMA Internal Medicine adds to the evidence that this strategy, while improving bone mineral density, may not reduce and may even worsen fractures.
Bisphosphonates adversely affect orthodontic treatment
Bisphosphonates are drugs used to increase bone density by killing off the cells that resorb old bone (osteoclasts) to 'make room' for new bone cells. Bisphosphonates include alendronate (Fosamax and Binosto), zoledronic acid (Reclast), risedronate (Actonel) and ibandronate (Boniva)...A study just published in the American Journal of Orthodontics & Dentofacial Orthopedics documents adverse effects of bisphosphonates on orthodontic outcomes.